Freenome vs GRAIL (2026)

AI Health Index verifiedSeptember 29, 2026
Verdict

Both screen blood for cancer signals using cell free DNA methylation and machine learning, and they differ in scope and regulatory standing. Freenome's SimpleScreen CRC looks for one cancer: FDA approved it in July 2026 for colorectal cancer screening in average risk adults aged 45 and older, with a positive result followed by colonoscopy. GRAIL's Galleri looks for more than 50 cancer types and predicts where a signal comes from. It is offered as a laboratory developed test in addition to guideline screening, with its FDA application pending. The randomized NHS-Galleri trial of 142,250 people did not meet its primary endpoint of fewer stage III or IV cancers after three rounds. Freenome replaces or supplements one established screen with an approved test; Galleri adds a broad screen on top of existing ones, and its outcome evidence is still settling.

The case for Freenome
  • A single cancer screen approved by FDA in July 2026, for colorectal cancer in average risk adults 45 and older.
  • Validation in 48,995 adults, reporting 79.2 percent sensitivity for cancer and 12.5 percent for advanced precancerous lesions.
  • US commercial rights held by Abbott, with launch planned for fall 2026.
The case for GRAIL
  • A multi cancer screen across more than 50 cancer types, with a predicted site of origin.
  • A laboratory developed test used in addition to guideline screening, with an FDA application pending.
  • A published list price of $949 per test.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Freenome and GRAIL are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

At a Glance

Plain facts

Fact Freenome GRAIL
Primary category Diagnostics & Genomics Diagnostics & Genomics
Founded 2014 2016
Headquarters Brisbane, California Sunnyvale, California
Website freenome.com grail.com
Attribute Matrix

Side by Side

Select any grade to read the note behind it.

Axis
F
Freenome
G
GRAIL
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Model Supply Chain Disclosure
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
AI Liability and Recourse
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Change Log

Product updates

The latest logged changes from each vendor, newest first, each linked to its source.

Freenome

  • Product / capability

    Freenome launched SimpleScreen Lung, a laboratory developed blood test for adults 50 to 80 with a smoking history of 20 or more pack years who are not in guideline screening.

    Source
  • Clinical evidence

    Freenome released pivotal validation results for an updated SimpleScreen CRC blood test with assay and algorithm changes, presented at ACG 2026.

    Source
All 2 Freenome updates →

GRAIL

  • Clinical evidence

    A PATHFINDER 2 analysis presented at AMCP Nexus 2026 reported Galleri results in 15,953 adults aged 65 and older followed for 12 months.

    Source
  • Regulatory / FDA

    The FDA Molecular and Clinical Genetics Devices Panel voted on GRAIL's Premarket Approval application for the Galleri multi cancer early detection blood test, for screening adults aged 50 and older.

    Source
  • Clinical evidence

    Nature Medicine published Galleri test performance from the randomized NHS-Galleri trial across three annual screening rounds in England.

    Source
All 4 GRAIL updates →
Citable Summaries

Each vendor in one paragraph

Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.

Freenome

Cancer screening company (NASDAQ: FRNM) whose blood tests run on a multiomics platform that reads cell free DNA methylation at single base resolution, alongside protein and autoantibody signals, with machine learning classifiers producing the result.

Source: AI Health Index, September 2026

GRAIL

Multi cancer early detection company (NASDAQ: GRAL). The Galleri test uses targeted methylation sequencing of cell free DNA from a blood draw, with machine learning classifiers that detect a cancer signal and predict its origin, across more than 50 cancer types. It is prescription only, offered as a laboratory developed test from GRAIL's CLIA certified, CAP accredited laboratory in Durham, North Carolina, and intended for use in addition to guideline recommended screening.

Source: AI Health Index, September 2026

FAQ

Questions buyers ask

How do Freenome and GRAIL work with the EHR?

The health systems page offers Founding Partners Freenome Digital Health, described as EHR native digital tools that identify eligible patients, engage patients and care teams and fit screening into routine care, with clinical and EHR workflow optimization as part of the program.

GRAIL announced a collaboration with Epic in April 2026 to make Galleri orderable, with results available, inside Epic through Aura, with implementation begun in the first quarter of 2026, early adopter programs underway and broad availability expected by the end of 2026; Ochsner Health's chief population health officer is quoted on the plan. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.

How are Freenome and GRAIL priced and sold?

Freenome sells its own configuration to health systems through a Founding Partner program: SimpleScreen Lung, a laboratory developed test, with SimpleScreen CRC and its digital tools. Since 20 October 2026 a provider can add SimpleScreen CRC to a SimpleScreen Lung order.

For GRAIL, some TRICARE plans cover the test, and Priority Health covers it in two Medicare Advantage plans. Galleri.com now offers the test online for $699, or $599 through a provider, and says discounted prices may be available through certain employers and insurers. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.

How do Freenome and GRAIL handle patient data?

Freenome's HIPAA notice of privacy practices (effective 13 July 2026) states that it never shares a patient's information for marketing or sale without written permission, and that it may use or share information for health research.

GRAIL's HIPAA notice of privacy practices covers test results and genetic information, and states that GRAIL will not sell a patient's PHI without written authorization and will not disclose it to third parties for marketing without authorization. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.

How much do Freenome and GRAIL leave to the clinician?

For Freenome, a positive result is followed by colonoscopy; after a negative result screening continues on clinical judgment, and a repeat test is due in three years if the patient chooses it again.

With GRAIL, each result has a stated next step. A No Cancer Signal Detected result does not rule out cancer, and the patient continues recommended screening. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers.

Disclosure

Both records were reviewed on this site in September 2026. GRAIL publishes a list price of $949 for Galleri; Freenome does not publish a price. The randomized NHS-Galleri trial did not meet its primary endpoint of fewer late stage cancers.

Ask both what their test's false positive rate is in people your practice would screen, and what follow up it triggers.